BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy
BioNexus Gene Lab Corp (NASDAQ: BGLC) has announced a strategic partnership with ML Tech to enhance its Ethereum-based treasury strategy. ML Tech, an AI-driven wealth management platform regulated by the National Futures Association, will provide BGLC with tailored investment solutions for optimizing its Ethereum holdings.
The partnership aims to leverage ML Tech's institutional-grade trading strategies and advanced quantitative models while maintaining strict risk management protocols. ML Tech's non-custodial execution model will enable BGLC to optimize its Ethereum holdings while ensuring transparency and security.
This collaboration aligns with BGLC's strategic vision of integrating blockchain technologies into its financial operations, focusing on growing Ethereum reserves while maintaining liquidity and control. ML Tech was selected for its expertise in delta-neutral and market-neutral strategies, serving institutional investors seeking low-correlation digital asset strategies.
BioNexus Gene Lab Corp (NASDAQ: BGLC) ha annunciato una partnership strategica con ML Tech per migliorare la sua strategia di tesoreria basata su Ethereum. ML Tech, una piattaforma di gestione patrimoniale guidata dall'IA e regolamentata dalla National Futures Association, fornirà a BGLC soluzioni di investimento personalizzate per ottimizzare le sue partecipazioni in Ethereum.
La partnership mira a sfruttare le strategie di trading di livello istituzionale e i modelli quantitativi avanzati di ML Tech, mantenendo rigorosi protocolli di gestione del rischio. Il modello di esecuzione non-custodial di ML Tech consentirà a BGLC di ottimizzare le sue partecipazioni in Ethereum garantendo al contempo trasparenza e sicurezza.
Questa collaborazione si allinea con la visione strategica di BGLC di integrare le tecnologie blockchain nelle sue operazioni finanziarie, concentrandosi sulla crescita delle riserve di Ethereum mantenendo liquidità e controllo. ML Tech è stata selezionata per la sua esperienza in strategie delta-neutre e market-neutre, servendo investitori istituzionali che cercano strategie di asset digitali a bassa correlazione.
BioNexus Gene Lab Corp (NASDAQ: BGLC) ha anunciado una asociación estratégica con ML Tech para mejorar su estrategia de tesorería basada en Ethereum. ML Tech, una plataforma de gestión de patrimonio impulsada por IA y regulada por la National Futures Association, proporcionará a BGLC soluciones de inversión personalizadas para optimizar sus tenencias de Ethereum.
La asociación tiene como objetivo aprovechar las estrategias de trading de nivel institucional y los modelos cuantitativos avanzados de ML Tech, manteniendo estrictos protocolos de gestión de riesgos. El modelo de ejecución no custodial de ML Tech permitirá a BGLC optimizar sus tenencias de Ethereum mientras garantiza transparencia y seguridad.
Esta colaboración se alinea con la visión estratégica de BGLC de integrar tecnologías blockchain en sus operaciones financieras, centrándose en aumentar las reservas de Ethereum mientras mantiene liquidez y control. ML Tech fue seleccionada por su experiencia en estrategias delta-neutras y market-neutras, sirviendo a inversores institucionales que buscan estrategias de activos digitales de baja correlación.
BioNexus Gene Lab Corp (NASDAQ: BGLC)는 ML Tech와 전략적 파트너십을 체결하여 Ethereum 기반의 재무 전략을 강화한다고 발표했습니다. ML Tech는 National Futures Association에 의해 규제된 AI 기반 자산 관리 플랫폼으로, BGLC에 맞춤형 투자 솔루션을 제공하여 Ethereum 보유 자산을 최적화할 것입니다.
이번 파트너십은 ML Tech의 기관급 거래 전략과 고급 정량 모델을 활용하면서 엄격한 리스크 관리 프로토콜을 유지하는 것을 목표로 합니다. ML Tech의 비수탁 실행 모델은 BGLC가 Ethereum 보유 자산을 최적화하면서도 투명성과 보안을 보장할 수 있도록 합니다.
이 협력은 BGLC의 재무 운영에 블록체인 기술을 통합하려는 전략적 비전과 일치하며, 유동성과 통제를 유지하면서 Ethereum 보유량을 증가시키는 데 중점을 둡니다. ML Tech는 저상관 디지털 자산 전략을 찾는 기관 투자자에게 서비스를 제공하는 델타 중립 및 시장 중립 전략에 대한 전문성으로 선택되었습니다.
BioNexus Gene Lab Corp (NASDAQ: BGLC) a annoncé un partenariat stratégique avec ML Tech pour améliorer sa stratégie de trésorerie basée sur Ethereum. ML Tech, une plateforme de gestion de patrimoine alimentée par l'IA et régulée par la National Futures Association, fournira à BGLC des solutions d'investissement sur mesure pour optimiser ses avoirs en Ethereum.
Le partenariat vise à tirer parti des stratégies de trading de niveau institutionnel et des modèles quantitatifs avancés de ML Tech tout en maintenant des protocoles stricts de gestion des risques. Le modèle d'exécution non-custodial de ML Tech permettra à BGLC d'optimiser ses avoirs en Ethereum tout en garantissant transparence et sécurité.
Cette collaboration s'inscrit dans la vision stratégique de BGLC d'intégrer les technologies blockchain dans ses opérations financières, en se concentrant sur la croissance des réserves d'Ethereum tout en maintenant liquidité et contrôle. ML Tech a été sélectionnée pour son expertise en stratégies delta-neutres et market-neutres, servant des investisseurs institutionnels à la recherche de stratégies d'actifs numériques à faible corrélation.
BioNexus Gene Lab Corp (NASDAQ: BGLC) hat eine strategische Partnerschaft mit ML Tech angekündigt, um seine Ethereum-basierte Treasury-Strategie zu verbessern. ML Tech, eine KI-gesteuerte Vermögensverwaltungsplattform, die von der National Futures Association reguliert wird, wird BGLC maßgeschneiderte Investitionslösungen zur Optimierung seiner Ethereum-Bestände bieten.
Die Partnerschaft zielt darauf ab, die institutionellen Handelsstrategien und fortschrittlichen quantitativen Modelle von ML Tech zu nutzen und gleichzeitig strenge Risikomanagementprotokolle aufrechtzuerhalten. Das nicht-treuhänderische Ausführungsmodell von ML Tech wird es BGLC ermöglichen, seine Ethereum-Bestände zu optimieren und dabei Transparenz und Sicherheit zu gewährleisten.
Diese Zusammenarbeit steht im Einklang mit der strategischen Vision von BGLC, Blockchain-Technologien in seine Finanzoperationen zu integrieren, wobei der Schwerpunkt auf dem Wachstum der Ethereum-Reserven bei gleichzeitiger Wahrung von Liquidität und Kontrolle liegt. ML Tech wurde aufgrund seiner Expertise in delta-neutralen und marktneutralen Strategien ausgewählt, die institutionellen Investoren dienen, die nach digitalen Vermögensstrategien mit niedriger Korrelation suchen.
- Partnership with regulated AI-driven wealth management platform
- Access to institutional-grade trading strategies
- Non-custodial execution model maintaining control of assets
- Enhanced risk management protocols for Ethereum holdings
- Exposure to volatile cryptocurrency market risks
- Dependency on third-party platform for treasury management
- Potential regulatory uncertainties in crypto asset management
Insights
BioNexus Gene Lab's partnership with ML Tech represents a strategic evolution in corporate treasury management that merges traditional finance with blockchain technology. This collaboration explicitly focuses on optimizing BGLC's Ethereum holdings through ML Tech's quantitative trading expertise and AI-driven platform.
The partnership has several noteworthy dimensions:
- BGLC gains access to ML Tech's institutional-grade trading strategies without surrendering custody of assets
- The implementation of delta-neutral and market-neutral strategies suggests a sophisticated approach to managing cryptocurrency volatility
- The non-custodial execution model maintains security while potentially enhancing returns
This move signals BGLC's commitment to alternative treasury management approaches amid broader institutional interest in digital assets. While traditional companies typically maintain cash reserves in conservative instruments like T-bills, BGLC is exploring cryptocurrency not just as a speculative asset but as a strategic treasury component.
The partnership could provide BGLC with competitive advantages in capital efficiency if successful, though it also introduces additional complexity and potential volatility to their balance sheet. ML Tech's regulatory standing with the NFA adds a layer of compliance oversight that may help mitigate some risks inherent in cryptocurrency markets.
For a smaller cap company like BGLC (
KUALA LUMPUR, Malaysia, March 08, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to innovation in the digital and healthcare space, has announced a strategic partnership with ML Tech to optimize the BGLC’s Ethereum-based growth strategies. ML Tech is an AI-driven wealth management platform for digital assets regulated by the National Futures Association (NFA), and is headquartered in Miami, Florida. This collaboration follows the announced Ethereum treasury strategy by BGLC, marking its commitment to technological and financial innovation.
Through this partnership, BGLC plans to leverage ML Tech’s cutting-edge digital asset trading infrastructure to grow its Ethereum holdings. ML Tech, known for its institutional-grade trading strategies and advanced quantitative models, will provide BioNexus with tailored investment solutions designed to maximize returns while maintaining stringent risk management protocols.
“We are excited to collaborate with BioNexus Gene Lab Corp to bring our innovative Ethereum yield strategies to their treasury operations,” said Leo Mindyuk, CEO and CIO of ML Tech. “Our quantitative trading expertise and non-custodial execution model will empower BGLC to optimize its Ethereum holdings while preserving full transparency and security.”
This partnership is aligned with BGLC’s broader strategic vision of integrating blockchain technologies into its financial operations. By leveraging ML Tech’s AI-driven wealth management platform, BGLC envisions growing its Ethereum reserves while maintaining liquidity and control. The partnership also foreshadows the possibility of innovative financial structures for the open market.
“The decision to implement an Ethereum treasury strategy underscores our commitment to improving shareholder value through innovation in the digital, AI driven future,” said Sam Tan, CEO of BioNexus Gene Lab Corp. “Partnering with ML Tech enables us to leverage our assets with an expert in the field to enhance the efficiency and performance of our treasury operations.”
BGLC chose ML Tech’s platform because it recognized it is built to serve institutional investors seeking low-correlation digital asset strategies. With a strong track record in delta-neutral and market-neutral strategies, ML Tech provides investors with sophisticated quantitative solutions that navigate the complexities of digital asset markets.
About BioNexus Gene Lab Corp: BioNexus Gene Lab Corp. (NASDAQ: BGLC) is a technology company committed to pioneering advancements in the digital and healthcare space. With a focus on integrating innovative technologies, BGLC seeks to ensure sustainable growth and value for shareholders. For more information visit https://www.bionexusgenelab.com/ethstrategy.
About ML Tech: ML Tech is an institutional digital asset platform that provides optimized blended portfolios and bespoke trading strategies. Through its marketplace, investors gain access to real-time NAV, portfolio insights, and a suite of market-neutral and smart beta strategies. For more information, visit www.mltech.ai or contact allocators@mltech.ai.
For investor inquiries or media requests, please contact:
IR@BIONEXUSGENELAB.COM
Forward-Looking Statements:
This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those projected due to various factors, including market conditions and regulatory developments. BioNexus Gene Lab Corp. assumes no obligation to update forward-looking statements, except as required by law.
FAQ
What is the purpose of BGLC's partnership with ML Tech for Ethereum treasury management?
How will ML Tech's platform benefit BGLC's Ethereum strategy?
What type of trading strategies will ML Tech implement for BGLC's Ethereum holdings?
How does this partnership align with BGLC's broader strategic vision?
